Translating world leading research in NMT into novel medicines

Myricx Pharma (“Myricx”) is an oncology drug discovery company developing precision medicines using its proprietary N-myristoyltransferases (NMT) platform.

We are building a pipeline of oncology programmes based on high-quality proprietary chemical inhibitors of NMT (NMTi), both as small molecule drugs and as novel potent cytotoxic payloads for antibody drug conjugates (ADCs) that are selective for specific cancer cell types.

The Company is based on breakthrough discoveries from the research laboratories of its co-founders, Professor Ed Tate, Dr Roberto Solari and Dr Andrew Bell, that unlocked an unexpected and unique mechanism of cancer cell killing, specific to cancers with vulnerabilities associated with the unfolded protein response.